Table 3.
Repeat-dose administration of oral THU-DAC in 4 baboons: effects on HbF percentage and neutrophil and platelet counts
| Baboon no. | DAC dose, mg/m2* | Schedule | Pretreatment HbF, % | Peak HbF, % | ΔHbF | ANC nadir, ×109/L | Platelet count maximum, ×109/L |
|---|---|---|---|---|---|---|---|
| 7470 | 5 | 2×/wk for 8 wks | 9.9 | 29.3 | 29.3 | 2.13 | 895 |
| 7472 | 5 | 2×/wk for 8 wks | 12.8 | 30.1 | 30.1 | 1.46 | 600 |
| 7482 | 10 | 3×/wk for 3 wks 2×/wk for 5 wks | 3.5 | 23.8 | 20.3 | 2.58 | 1004 |
| 7484 | 10 | 2×/wk for 8 wks | 4.2 | 23.1 | 23.1 | 1.68 | 1029 |
Two of these animals had relatively low bioavailability (baboons PA7472 and PA7482) and 2 had relatively high oral THU-DAC bioavailability (baboons PA7484 and PA7470) according to the pharmacokinetic studies.
ANC indicates absolute neutrophil count.
*
Administered after THU 400 mg/m2.